ENGOT-OV24 / NSGO-AVANOVA2

Niraparib and niraparib-bevacizumab combination against bevacizumab alone in Women with Homologous Recombination Deficient (HRD) platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer. 

Contact Person
Status
Completed
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
GOG-F
GCIG Number